Closely-held Minghui Pharmaceutical enrolled the first patient in the Phase 3 clinical study for MH004 cream targeting mild-to-moderate atopic dermatitis, a prevalent skin condition.
The randomized, double-blind, and placebo-controlled Phase 3 clinical trial aims to evaluate the safety and efficacy of the investigational topical cream in a larger patient population.
The company remains optimistic about the trial’s progress and anticipates sharing the topline data of the Phase 3 trial in the second half of 2024, with the goal of providing a potential breakthrough treatment option for patients living with mild-to-moderate atopic dermatitis.
